Literature DB >> 28187815

Principles of intracranial pressure monitoring and treatment.

M Czosnyka1, J D Pickard2, L A Steiner3.   

Abstract

Intracranial pressure (ICP) is governed by volumes of intracranial blood, cerebrospinal fluid, and brain tissue. Expansion of any of these volumes will trigger compensatory changes in the other compartments, resulting in initially limited change in ICP. Due to the rigid skull, once compensatory mechanisms are exhausted, ICP rises very rapidly. Intracranial hypertension is associated with unfavorable outcome in brain-injured patients. This chapter discusses the pathophysiology of raised ICP, as well as typical waveforms, monitoring techniques, and clinical management. The dynamics of ICP are more important than the absolute value at any given time point, but mean ICP exceeding 20-25mmHg is usually treated aggressively. Algorithms based on data from patients with traumatic brain injury are applied also in other conditions. However, an understanding of the underlying pathophysiology allows adaptation of therapies to other pathologies. Typically, a three-staged approach is used, starting with restoration of systemic physiology, sedation, and analgesia. If these measures are insufficient, surgical options, such as drainage of cerebrospinal fluid or evacuation of mass lesions, are considered. In the absence of surgical options, stage 2 treatments are initiated, consisting of either mannitol or hypertonic saline. If these measures are insufficient, stage 3 therapies include hypothermia, metabolic suppression, or craniectomy.
© 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Intracranial Pressure; cerebral autoregulation; management; outcome; traumatic brain injury

Mesh:

Year:  2017        PMID: 28187815     DOI: 10.1016/B978-0-444-63600-3.00005-2

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  7 in total

1.  Intracranial pressure changes after mild traumatic brain injury: a systematic review.

Authors:  Mohammad Nadir Haider; John J Leddy; Andrea L Hinds; Nell Aronoff; Diane Rein; David Poulsen; Barry S Willer
Journal:  Brain Inj       Date:  2018-04-27       Impact factor: 2.311

Review 2.  The Role of Substance P in Secondary Pathophysiology after Traumatic Brain Injury.

Authors:  Robert Vink; Levon Gabrielian; Emma Thornton
Journal:  Front Neurol       Date:  2017-06-28       Impact factor: 4.003

3.  Large-Volume Intrathecal Administrations: Impact on CSF Pressure and Safety Implications.

Authors:  Vasily Belov; Janine Appleton; Stepan Levin; Pilar Giffenig; Beata Durcanova; Mikhail Papisov
Journal:  Front Neurosci       Date:  2021-04-14       Impact factor: 4.677

4.  A recurrent machine learning model predicts intracranial hypertension in neurointensive care patients.

Authors:  Nils Schweingruber; Marius Marc Daniel Mader; Anton Wiehe; Frank Röder; Jennifer Göttsche; Stefan Kluge; Manfred Westphal; Patrick Czorlich; Christian Gerloff
Journal:  Brain       Date:  2022-08-27       Impact factor: 15.255

5.  Long-term monitoring of intracranial pressure in freely-moving rats; impact of different physiological states.

Authors:  Sajedeh Eftekhari; Connar Stanley James Westgate; Katrine Printz Johansen; Signe Rath Bruun; Rigmor H Jensen
Journal:  Fluids Barriers CNS       Date:  2020-06-09

Review 6.  The Evolution of the Role of External Ventricular Drainage in Traumatic Brain Injury.

Authors:  Charlene Y C Chau; Claudia L Craven; Andres M Rubiano; Hadie Adams; Selma Tülü; Marek Czosnyka; Franco Servadei; Ari Ercole; Peter J Hutchinson; Angelos G Kolias
Journal:  J Clin Med       Date:  2019-09-10       Impact factor: 4.241

Review 7.  Timing of surgical intervention for compartment syndrome in different body region: systematic review of the literature.

Authors:  Federico Coccolini; Mario Improta; Edoardo Picetti; Luigi Branca Vergano; Fausto Catena; Nicola de 'Angelis; Andrea Bertolucci; Andrew W Kirkpatrick; Massimo Sartelli; Paola Fugazzola; Dario Tartaglia; Massimo Chiarugi
Journal:  World J Emerg Surg       Date:  2020-10-21       Impact factor: 5.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.